Ngā hua rapu kaituhi :: APM

1

Heart Failure in Patients with Diabetes and Chronic Kidney Disease: Challenges and Opportunities mā Kris Vijay, Brendon L. Neuen, Edgar V. Lerma

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
2

Empagliflozin in Patients with Chronic Kidney Disease mā Brendon L. Neuen, Robert A. Fletcher, Hiddo J.L. Heerspink

I whakaputaina 2023

Whiwhi kuputuhi katoa
Carta

Tiaki ki tētahi rārangi

I tiakina i:
3

Chronic kidney disease and the global NCDs agenda mā Brendon L. Neuen, Steven J. Chadban, Alessandro Demaio, David W. Johnson, Vlado Perkovic

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Editorial

Tiaki ki tētahi rārangi

I tiakina i:
4

Chronic kidney disease mā Kamyar Kalantar‐Zadeh, Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic

I whakaputaina 2021

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomised control trials mā Edward W. Webster, Adam Perkovic, Brendon L. Neuen, Katherine R. Tuttle, Vlado Perkovic

I whakaputaina 2025

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Predictors of Patency after Balloon Angioplasty in Hemodialysis Fistulas: A Systematic Review mā Brendon L. Neuen, Ronny Gunnarsson, Angela C Webster, Richard Baer, Jonathan Golledge, Murty L. Mantha

I whakaputaina 2014

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

Neutrophil–lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients mā Brendon L. Neuen, Nicole Leather, A.M. Greenwood, Ronny Gunnarsson, Yeoungjee Cho, Murty L. Mantha

I whakaputaina 2015

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
8

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review mā Merlin C. Thomas, Brendon L. Neuen, Stephen M. Twigg, Mark E. Cooper, Sunil V. Badve

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes mā Jingwei Li, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Brendon L. Neuen, Clare Arnott, Robin Simpson, Richard Oh, Kenneth W. Mahaffey, Hiddo J.L. Heerspink

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
10

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis... mā Tadashi Toyama, Brendon L. Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg Jardine, Hiddo J.L. Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada, Vlado Perkovic

I whakaputaina 2019

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
11

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials mā Sheldon W. Tobe, Thomas A. Mavrakanas, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee, Brendon L. Neuen, Vlado Perkovic, Kenneth W. Mahaffey, Wally Rapattoni, Fernando G. Ang

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
12

Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis mā Clare Arnott, Qiang Li, Amy Kang, Brendon L. Neuen, Séverine Bompoint, Carolyn S.P. Lam, Anthony Rodgers, Kenneth W. Mahaffey, Christopher P. Cannon, Vlado Perkovic, Meg Jardine, Bruce Neal

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
13

Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the <scp>CANVAS</scp> Program and <scp>CREDENCE</scp> trial mā Jennifer Barraclough, Jie Yu, Gemma A. Figtree, Vlado Perkovic, Hiddo J.L. Heerspink, Brendon L. Neuen, Christopher P. Cannon, Kenneth W. Mahaffey, Aletta E. Schutte, Bruce Neal, Clare Arnott

I whakaputaina 2022

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
14

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the D... mā Akihiko Koshino, Brendon L. Neuen, Niels Jongs, Carol A. Pollock, Peter J. Greasley, Eva-Marie Andersson, Ann Hammarstedt, Cecilia Karlsson, Anna Maria Langkilde, Takashi Wada, Hiddo J.L. Heerspink

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
15

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program mā Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Qiang Li, Meg Jardine, Richard Oh, Hiddo J.L. Heerspink, Vlado Perkovic

I whakaputaina 2019

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
16

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program mā Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS mā Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal, Clare Arnott, Vlado Perkovic, Paul M. Ridker, Katherine R. Tuttle, Michael K. Hansen, Hiddo J.L. Heerspink

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
18

Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis mā Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, Adam Perkovic, Muthiah Vaduganathan, Sunil V. Badve, Katherine R. Tuttle, Richard E. Pratley, Hertzel C. Gerstein, Vlado Perkovic, Hiddo J.L. Heerspink

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
19

The effect of canagliflozin on amputation risk in the <scp>CANVAS</scp> program and the <scp>CREDENCE</scp> trial mā Clare Arnott, Yuli Huang, Brendon L. Neuen, Gian Luca Di Tanna, Christopher P. Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic, Meg Jardine, Kenneth W. Mahaffey, Bruce Neal

I whakaputaina 2020

Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
20

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis mā Brendon L. Neuen, T. Kue Young, Hiddo J.L. Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W. Mahaffey, David M. Charytan, David C. Wheeler, Clare Arnott, Séverine Bompoint, Adeera Levin, Meg Jardine

I whakaputaina 2019

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i: